![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 44, 31734-31739, October 29, 1999
From the Department of Pathology, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107
The overexpression of Bax kills cells by a
mechanism that depends on induction of the mitochondrial permeability
transition (MPT) (Pastorino, J. G., Chen, S.-T., Tafani, M.,
Snyder, J. W., and Farber, J. L. (1998) J. Biol.
Chem. 273, 7770-7775). In the present study, purified,
recombinant Bax opened the mitochondrial permeability transition pore
(PTP). Depending on its concentration, Bax had two distinct effects. At
a concentration of 125 nM, Bax caused the release of the
intermembranous proteins cytochrome c and adenylate kinase
and the release from the matrix of sequestered calcein, effects
prevented by the inhibitor of the PTP cyclosporin A (CSA). At this
concentration of Bax, there was no detectable mitochondrial swelling or
depolarization. These effects of low Bax concentrations are interpreted
as the consequence of transient, non-synchronous activation of the PTP
followed by a prompt recovery of mitochondrial integrity. By contrast,
Bax concentrations between 250 nM and 1 µM
caused a sustained opening of the PTP with consequent persistent
mitochondrial swelling and deenergization (the MPT). CSA prevented the
MPT induced by Bax. Increasing concentrations of calcium caused a
greater proportion of the mitochondria to undergo the MPT in the
presence of Bax. Importantly, two known mediators of apoptosis,
ceramide and GD3 ganglioside, potentiated the induction by Bax of the
MPT. The data imply that Bax mediates the opening of the mitochondrial
PTP with the resultant release of cytochrome c from the
intermembranous space.
Bax is a proapoptotic member of the Bcl-2 family of proteins (2,
3). By utilizing inducible expression systems, the production of Bax
was shown to induce the characteristic features of apoptosis, including
cell death, DNA fragmentation, and caspase activation (1, 4). Moreover,
the overexpression of Bax resulted in mitochondrial dysfunction with
the loss of the membrane potential and the release of cytochrome
c to the cytosol (1), events that occur in many models of apoptosis.
Our studies show that the cell death resulting from the induced
overexpression of Bax was prevented by inhibition of the mitochondrial permeability transition with cyclosporin A (1). The
MPT1 was accompanied by the
release of cytochrome c from the mitochondria, caspase-3
activation in the cytosol, cleavage of the nuclear enzyme poly(ADP-ribose)polymerase, and DNA fragmentation, all of which were
inhibited by CSA. The caspase-3 inhibitor
benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone had no effect on
the loss of viability. These results indicated that in this model, at
least, cell death and caspase activation are independent downstream
consequences of the Bax-induced MPT. However, the mechanism coupling
the expression of Bax and the induction of the MPT remained to be defined.
Here we show that purified Bax induces the MPT in isolated
mitochondria, an event that is prevented by CSA and accompanied by
mitochondrial depolarization, organelle swelling, and the release of
cytochrome c. At lower concentrations of Bax, mitochondrial swelling and depolarization are not detected, but cytochrome
c and matrix-entrapped calcein are still released, changes
that are also prevented by CSA. Transient opening and closing of the PTP is the mechanism postulated to account for the effect of lower Bax
concentrations. Finally, ceramide and GD3 ganglioside, two lipid
messengers implicated in apoptotic signaling pathways, are shown to
potentiate the ability of Bax to induce the MPT.
Preparation of Purified Recombinant Bax--
Full-length Bax is
insoluble. Thus, polymerase chain reaction was used to generate a
fragment of the full-length mouse Bax cDNA that lacked the coding
region for the carboxyl-terminal 19 amino acids. The resulting cDNA
was inserted into the EcoRI and SmaI sites of
pGEX-4T-2 (Amersham Pharmacia Biotech). The plasmid (pGEXBax Isolation of Mitochondria and Measurement of the MPT by Swelling
of the Organelles--
Mitochondria from rat liver were isolated in a
sucrose-based medium containing 0.1 mM EGTA, 3 mM KH2PO4, 300 mM
sucrose, 1 mM MgCl2, pH 7.2, as described
previously (5). For experiments examining the effect of calcium on the
MPT in the presence of Bax, low calcium containing mitochondria were
isolated by flushing the liver with 0.25 M sucrose and 1 mM EGTA as described (5). Mitochondria (0.5 mg/ml) were
incubated in a KCl-based medium (150 mM KCl, 25 mM NaHCO3, 1 mM MgCl2,
3 mM KH2PO4, 20 mM
Hepes, pH 7.4). Glutamate and malate (1 mM, Sigma) were
added as respiratory substrates. Swelling was monitored at 540 nm in a
Perkin-Elmer split beam spectrophotometer with all components except
Bax in the reference cuvette. The percentage of swollen mitochondria was determined as described previously (6). Briefly, the MPT was
induced in mitochondria (0.5 mg/ml) with 150 µM
Ca2+ and 1 mM Pi. When swelling was
complete, 1 µM CSA and 0.1 µM ruthenium red
were added. An equal volume of fresh mitochondria (0.5 mg/ml) was then
added. The CSA and ruthenium red prevent the MPT from developing in the
freshly added mitochondria. The final absorbance reading corresponds to
50% swollen mitochondria and 50% nonswollen mitochondria. By varying
the percentage of swollen and nonswollen mitochondria, a calibration
curve is constructed that reflects the change in absorbance as a
function of the percentage of swollen mitochondria (6).
CSA was dissolved in ethanol and added to the mitochondria for a final
concentration of 5 µM. In all cases mitochondria were pretreated with CSA for at least 2 min prior to the addition of other
agents. C2- and C16-ceramides and GD3
ganglioside were dissolved in Me2SO and added to the
mitochondria for a final concentration of 1 µM and 500 nM, respectively. Dihydroceramide and GM3 ganglioside were
also dissolved in Me2SO and added to the mitochondria for a
final concentration of 10 and 1 µM, respectively.
Atractyloside was dissolved in Me2SO and added to the
mitochondria at a final concentration of 5 µM. In all
cases, the final concentration of Me2SO was 0.2%, and
Me2SO alone had no effect on the parameters measured.
Measurement of Mitochondrial Energization--
Mitochondrial
energization was measured with a TPP+-selective electrode
as described (7). Calcein was introduced into the matrix space of the
mitochondria by incubating them with a 5 µM concentration
of the membrane-permeant ester form, calcein-AM. The mitochondria were
then washed twice with respiratory buffer. Calcein-loaded mitochondria
were exposed to various conditions as outlined under "Results."
Following such treatments, the mitochondria were washed and the
fluorescence measured on a Perkin-Elmer LS-5 fluorescence
spectrophotometer at 488 nm excitation and 520 nm emission.
Measurement of Cytochrome c Release--
The mitochondria were
first pelleted at 12,000 × g for 30 min at 4 °C.
The supernatant was removed and filtered through a 0.2-µm and then
through a 0.1-µm Ultrafree MC filter (Millipore). Mitochondrial and
supernatant fractions were normalized for protein content and separated
on 12% SDS-polyacrylamide gels and electroblotted onto nitrocellulose
membranes. Cytochrome c was detected by a monoclonal
antibody to cytochrome c (PharMingen, San Diego, CA) as
described previously (1).
Measurement of Adenylate Kinase Release--
As with cytochrome
c release the mitochondria were pelleted at 12,000 × g for 30 min at 4 °C. The supernatant was removed and
filtered through a 0.2-µm and then through a 0.1- µm Ultrafree MC
filter (Millipore). Adenylate kinase activity was assayed in the
supernatant spectrophotometrically at 25 °C (8, 9). ADP formation is
coupled with phosphoenolpyruvate, pyruvate kinase, and lactate
dehydrogenase; and NADH oxidation was measured at 340 nm. The assay
system contained 100 mM triethanolamine HCl buffer, pH 7.5;
130 mM KCl, 3.2 mM MgSO4, 3 mM ATP, 0.38 mM NADH, 0.68 mM
phosphoenolpyruvate, 30 units of pyruvate kinase, and lactate
dehydrogenase in a total volume of 3 ml. Total adenylate kinase
activity in mitochondria was determined by disruption of the
mitochondria with 0.5% Triton X-100.
Induction of the MPT by Bax in Isolated Mitochondria--
The MPT
is readily detected in isolated mitochondria by the large amplitude
swelling of these organelles. Swelling is assessed as the decrease in
absorbance at 540 nm of the mitochondrial suspension. Fig.
1, left panel, shows that the
addition of recombinant Bax to respiring mitochondria induced the MPT
in a concentration-dependent manner. Whereas 1 µM Bax induced the rapid and complete swelling of the
mitochondrial population, 500 and 250 nM Bax induced
swelling in about 70 and 40% of the organelles, respectively.
The concentration dependence and time course of the effect of Bax on
organelle swelling was paralleled by changes in the mitochondrial membrane potential. Fig. 1, right panel, shows that 1 µM Bax induced a rapid and complete loss of the
mitochondrial membrane potential as measured by a release of
sequestered TPP+. Similar to the effect on swelling, 500 and 250 nM Bax had intermediate effects. In parallel with
the absence of swelling, 125 nM Bax had no detectable
effect on mitochondrial energization as demonstrated by the inability
to observe an increase in external TPP+.
Fig. 1, right panel, would seemingly indicate that a rebound
in the membrane potential occurred in mitochondria exposed to 500 and
250 nM Bax. Membrane potential was measured with a
TPP+-sensitive electrode, and the rebound noted most likely
represents a reaccumulation of the TPP+ released from
depolarized mitochondria by mitochondria that are still energized.
Supporting this interpretation was the fact that the addition of 10 µM of the uncoupler carbonyl cyanide
m-chlorophenylhydrazone caused a rapid depolarization of the
mitochondria and a re-release of the TPP+ (Fig. 1,
right panel).
Induction of the MPT by Bax Is Inhibited by CSA and Potentiated by
Atractyloside--
CSA is a potent inhibitor of induction of the MPT
in isolated mitochondria (10), and 5 µM CSA completely
inhibited the mitochondrial swelling and depolarization produced by 1 µM Bax (Fig. 1, left and right
panels).
To define further the involvement of the MPT in the Bax-induced
mitochondrial alterations, use was made of atractyloside. Atr binds to
the adenine nucleotide transporter, thereby stabilizing the enzyme in
the configuration where the nucleotide-binding site faces the cytosol
(the so-called c conformation) (11). Induction of the MPT is
facilitated by this configuration of the ANT (11). Fig.
2 shows that 5 µM Atr alone
did not induce the MPT, as measured by either sustained mitochondrial
swelling or loss of the membrane potential. Similarly, 125 nM Bax did not induce detectable mitochondrial swelling or
depolarization (Figs. 2 and 3). However,
in the presence of both 125 nM Bax and 5 µM
Atr, mitochondrial swelling was as rapid and complete (Fig. 2) as with
1 µM Bax (Fig. 1, right panel). Importantly,
the mitochondrial alterations produced by the combination of Atr and
Bax were completely prevented by CSA (Fig. 2).
Bax Induces Release of Cytochrome c and Adenylate Kinase from
Mitochondrial Intermembrane Space--
Bax produced a
concentration-dependent release of cytochrome c
from the intermitochondrial membrane space to the supernatant (Fig. 3).
An almost complete release of cytochrome c was achieved with
1 µM Bax, an effect that was completely inhibited by CSA (Fig. 3). Interestingly, 125 nM Bax did induce the release
of a proportion of the total cytochrome c, an effect that
was still inhibited by CSA (Fig. 3), even though the same concentration did not promote detectable swelling (Fig. 1, left
panel).
The release of cytochrome c was not a specific effect of Bax
on the mitochondria. Adenylate kinase, another mitochondrial protein
located in the intermembranous space (8, 9), was also released by Bax.
As with cytochrome c, increasing concentrations of Bax
resulted in the release of greater amounts of adenylate kinase (Fig.
4). 125 nM Bax released 26%
of the total adenylate kinase activity. As with the release of
cytochrome c, CSA inhibited the release of adenylate
kinase.
Bax Induces Release of Calcein from the Mitochondrial
Matrix--
The release by Bax of cytochrome c (Fig. 3) and
adenylate cyclase (Fig. 4) in the absence of mitochondrial swelling
(Fig. 1, left panel) likely represents the transient opening
and closing of the mitochondrial permeability transition pore (PTP).
This is indicated by the data in Fig. 5.
Upon induction of the MPT, calcein preloaded into the mitochondria is
lost from the matrix space (12). Mitochondria were preloaded with
calcein-AM. Nonspecific esterases remove the acetoxymethyl ester group,
thereby trapping the calcein (620 Da) in the mitochondrial matrix. Upon
exposure to 1 µM Bax, calcein fluorescence was promptly
lost from the preloaded mitochondria (Fig. 5), an effect that was again
totally prevented by CSA (Fig. 5). Although it produced no detectable
effects on mitochondrial swelling or membrane potential (Fig. 1), 125 nM Bax did cause a slow but steady release of calcein (Fig.
5). After a 20-min exposure to 125 nM Bax, the mitochondria
had lost 40% of their initial calcein fluorescence. Importantly, this
effect was inhibited by CSA (Fig. 5). These data suggest that lower
concentrations of Bax cause transient and non-synchronous opening and
prompt closing of the PTP. At any given moment, this effect in a
limited proportion of the total pool of mitochondria was not reflected in any depolarization or swelling upon observation of the entire population of these organelles. Nevertheless, transient opening and
closing of the PTP was reflected in the observed accumulation of
cytochrome c and calcein in the medium, as the release of
these matrix constituents is irreversible.
Ceramide and GD3 Ganglioside Potentiate Induction of the MPT by
Bax--
Ceramide and GD3 ganglioside have been demonstrated to
mediate apoptosis (13, 14). Ceramide has direct effects on the function
of isolated mitochondria (15), and GD3 ganglioside promotes
mitochondrial depolarization in intact cells (14). As shown in Fig.
6 (left panel), 1 µM C2-ceramide alone did not induce the MPT,
as measured by mitochondrial swelling. However, 125 nM Bax
and 1 µM C2-ceramide together rapidly induced
mitochondrial swelling (Fig. 6, left panel). Both these
effects were inhibited by CSA (Fig. 6, left panel). By
contrast, C2-dihydroceramide, which differs from
C2-ceramide in lacking only the trans double bond and does
not promote apoptosis (13), did not potentiate induction by Bax of the
MPT (Fig. 6, left panel). C16-ceramide is a
longer chain, endogenous species of ceramide that also induces apoptosis (16, 17). C16-ceramide also potentiated induction of the MPT by Bax (Fig. 6, right panel), an effect that was
inhibited by CSA. Diacylglycerol possesses a glycerol backbone rather
than the sphingosine of ceramide and had no effect on the MPT in the presence of Bax.
Finally, 500 nM GD3 ganglioside alone did not cause
mitochondrial swelling. However, when added together with 125 nM Bax, prompt swelling occurred, an effect that was again
inhibited by CSA (Fig. 7). Importantly,
the biosynthetic precursor of GD3 ganglioside, GM3 ganglioside, had no
effect on the ability of Bax to promote the MPT.
Dependence of MPT Induction by Bax on Mitochondrial
Ca2+--
The presence of Ca2+ in the
mitochondrial matrix is required to enable any one of a wide variety of
agents to induce the MPT in isolated mitochondria and in the intact
cell (18, 19). Interaction of Ca2+ with a poorly defined
binding site on the matrix side of the inner membrane is necessary for
pore opening. In turn, the probability of pore opening can be
manipulated by changes in the concentration of matrix Ca2+
(20-22). We show here that induction of the MPT by Bax is similarly regulated by Ca2+.
The addition of increasing amounts of Ca2+ to low calcium
mitochondria induced the MPT in an increasing fraction of the
organelles (Fig. 8A). In
control mitochondria, 120 µM Ca2+ induced the
MPT in 50% of the mitochondria and 160 µM in the entire
population. By contrast, in the presence of 125 nM Bax, a
much greater percentage of the mitochondria underwent the MPT at lower
concentrations of Ca2+ (Fig. 8B). 40 µM Ca2+ induced the MPT in less than 30% of
the mitochondria in the absence of Bax and in 60% of the mitochondria
in its presence. With 80 µM Ca2+ alone, the
MPT occurred in 30% of the mitochondria. In the presence of Bax, the
same concentration of Ca2+ induced the MPT in virtually all
of the mitochondria. Ceramide alone (Fig. 8C) had no effect
on the response of the mitochondria to successively increasing
concentrations of Ca2+. However, the combination of
ceramide and Bax sensitized the mitochondria to Ca2+ to an
even greater extent than did Bax alone. In the presence of 40 µM Ca2+, virtually all of the mitochondria
underwent the MPT (Fig. 8D).
The data presented above document that Bax has a number of effects
on isolated mitochondria, all of which can be ascribed to a single
mechanism, namely, activation of the mitochondrial PTP. Importantly,
similar consequences of the action of Bax on mitochondria can be
recognized from the reports of the effects of this apoptotic protein in
intact cells (1, 4). Thus, the data of the present study relate to the
mechanism of action of Bax in an intact cell, as well as under the
in vitro conditions reported here.
At the higher concentrations (250 nM to 1 µM), Bax caused mitochondrial swelling and deenergization
with the release of pre-loaded calcein from the matrix and cytochrome
c and adenylate kinase from intermembranous space. Calcium
ions potentiated and CSA prevented these observed effects of Bax, which
are all clearly attributable to activation of the PTP with induction of
the MPT. In turn, these direct effects of Bax on mitochondria in
vitro are parallel to those reported previously upon the induction
of Bax expression in stably transfected Jurkat T cells (1). Bax
overexpression resulted in induction of the MPT with release of
cytochrome c from the mitochondria to the cytosol,
effects that were prevented by CSA.
The release of cytochrome c from the mitochondrial
intermembrane space to the cytosol is increasingly perceived as a
critical event in many models of apoptosis (23, 24). As a consequence of its ability to activate caspases, cytochrome c is
positioned as a key factor following a mitochondrial injury in
initiating the execution phase of apoptosis. A current focus of debate
has been the role of the MPT in the release of cytochrome c.
Induction of the MPT in isolated mitochondria upon the uptake of
Ca2+ collapses the membrane potential and swells the
mitochondria with the consequent release of cytochrome c
(25).
At a lower concentration (125 nM), Bax caused the release
of cytochrome c and adenylate kinase from the
intermembranous space and calcein from the matrix, effects prevented by
CSA. This release, however, was not accompanied by detectable
mitochondrial swelling or deenergization. The CSA-sensitive release of
adenylate kinase from the intermembranous space indicates that the
effect on cytochrome c is not a specific one. The
CSA-sensitive release of calcein from the mitochondrial matrix
indicates that the action of the lower concentrations of Bax is not
limited to an alteration of the permeability properties of the outer
mitochondrial membrane but rather reflects a simultaneous change in the
inner membrane as well.
We would argue that there need be no mechanistic difference between
cytochrome c release at low or high Bax concentrations. The
apparent difference is a consequence of the detection methods. Transient and non-synchronous activation and then deactivation of the
mitochondrial PTP most readily explains these effects of lower Bax
concentrations. PTP opening of short duration in a limited proportion
of the total pool of mitochondria causes depolarization, swelling, and
release of a fraction of the total cytochrome c. Prompt
closure of the PTP allows reenergization with reaccumulation of
TPP+ and prevents the sustained, large amplitude swelling
that denotes the more stable induction of the MPT. Reenergization is
not precluded, because the release of small amounts of cytochrome
c does not inhibit respiration and maintenance of the
membrane potential under the non-phosphorylating conditions of the
present study. Indeed, depolarization followed by repolarization of
individual mitochondria brought about by transient opening of the PTP
has been reported in both isolated mitochondria and intact cells (26, 27). Previous reports of the induction by Bax in vitro of
cytochrome c release in the absence of mitochondrial
swelling or the loss of Arguments against the participation of the MPT in apoptosis have
emphasized that cytochrome c release in intact cells or from isolated mitochondria occurs before the onset of mitochondrial depolarization or in the absence of organelle swelling (28-31). Our
conclusion that the Bax-induced released of cytochrome c
from isolated mitochondria can occur as a result of transient
activation and deactivation of the PTP can readily explain these
previous attempts to account for cytochrome c release in the
absence of a demonstrable MPT. In other words, it is not necessary to
invoke any mechanism other than the PTP to explain the release of
cytochrome c from the mitochondria in apoptosis.
The present study has also found that ceramide potentiated induction of
the MPT by Bax. Although it deserves emphasizing that the relevance of
this observation to conditions occurring in the intact cell remains
unclear, ceramide has been implicated as a mediator of the apoptosis
that follows activation of death-inducing receptors (13). However,
there is some dispute as to the time course and mechanism of ceramide
production. Some studies suggest that ceramide is elevated very early
after ligand binding, as a consequence of the activation of an acidic
sphingomyelinase (32). By contrast, other studies suggest that ceramide
is elevated only later during the apoptotic process, by a mechanism
that is not dependent on acidic sphingomyelinase and that may involve de novo ceramide synthesis (33). In light of the ability of ceramide to potentiate induction of the MPT by Bax (Fig. 8), it is
conceivable that the late ceramide increase may help amplify any damage
that the mitochondria incur early on by Bax. Indeed the precursor of
ceramide, dihydroceramide, is in the mitochondria and endoplasmic
reticulum (13). The concentrations of ceramide reported associated with
mitochondria (2 nmol/mg mitochondrial protein) are in the same range as
the concentration of ceramide employed here (2.5 nmol/mg mitochondrial
protein). Interestingly, tumor necrosis factor treatment elevates
ceramide levels in mitochondria isolated from hepatocytes (34). Indeed,
upon treatment with tumor necrosis factor, the ceramide levels of
hepatocyte mitochondria went up to 6 nmol/mg protein (34). In addition,
the concentration of Bax in tumor cell lines has been reported to be
around 100 nM with a 10-fold increase upon exposure to
stimuli that induce apoptosis (28).
Ceramide may mediate some of its effects through GD3 ganglioside.
Prevention of GD3 synthesis from ceramide by inhibition of GD3
synthetase prevented Fas-induced apoptosis (14). In line with the
ability of GD3 to potentiate Bax induction of the MPT, addition of GD3
to hematopoietic cells resulted in a disruption of mitochondrial
membrane potential in a caspase-independent manner (14).
*
This work was supported by National Institutes of Health
Grant DK38305.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The abbreviations used are:
MPT, mitochondrial
permeability transition;
CSA, cyclosporin A;
TPP+, triphenylphosphonium ion;
Atr, atractyloside;
PTP, permeability
transition pore;
GST, glutathione S-transferase;
AM, acetoxymethyl ester.
Functional Consequences of the Sustained or Transient
Activation by Bax of the Mitochondrial Permeability Transition
Pore*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
19) was
used to transform the protease-deficient strain of Escherichia
coli, BL21. An overnight culture of bacteria was used to inoculate
(1:10) 2 liters of LB medium containing 100 µg/ml ampicillin and
incubated at 37 °C. When the A600 was between 0.7 and 1.0, isopropyl-1-thio-
-D-galactopyranoside was
added to a final concentration of 0.1 mM, and the bacteria
were incubated for an additional 3 h. The cells were recovered by
centrifugation (1000 × g for 10 min at 4 °C) and
lysed with 0.5 mg/ml lysozyme in 50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween 20, 5 mM dithiothreitol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 10 µg/ml aprotinin. The lysate was then
sonicated briefly on ice and centrifuged at 28,000 × g
for 10 min at 4 °C. The resulting supernatant was incubated with
glutathione-Sepharose at 4 °C for 8 h. The resin was washed
with 20 mM Tris, pH 8.0, 150 mM NaCl, 0.1%
Tween 20, and 5 mM dithiothreitol. The resin containing the bound GST-Bax
19 was incubated with 10 units of thrombin in
phosphate-buffered saline overnight at 4 °C with agitation. The
released Bax was then purified on a MonoQ column using a linear
gradient of 0.5 M NaCl, pH 5.0. The resulting eluate was
concentrated in a Micron concentrator (Millipore). GST lacking the
fused Bax
19 was subjected to the same purification as GST-Bax
19.
The resulting protein had no effect on the mitochondrial parameters
measured below, a result indicating that the action of Bax was not
due to GST itself or a contaminant of the purification process.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 1.
Bax induces the MPT as assessed by
mitochondrial swelling and depolarization. Purified recombinant
Bax was added to 0.5 mg/ml mitochondria in KCl-based respiratory buffer
at 37 °C. Respiration was initiated with the addition of 1 mM glutamate/malate. The absorbance change was monitored at
540 nm with all constituents except Bax in the reference cuvette. The
results are typical of 3 independent experiments utilizing 3 independent mitochondrial and Bax preparations. Mitochondrial membrane
potential was measured using a TPP+-selective electrode. 4 µM TPP+ was added to the mitochondria (0.5 mg/ml) in respiratory buffer containing 1 mM
glutamate/malate. After the sequestration of TPP+ by the
mitochondria had equilibrated, recombinant Bax was added at the
indicated concentrations. The results are typical of 3 independent
experiments utilizing 3 independent mitochondrial and Bax preparations.
CCCP, carbonyl cyanide
m-chlorophenylhydrazone.

View larger version (16K):
[in a new window]
Fig. 2.
Atractyloside potentiates Bax-induced
mitochondrial swelling. Mitochondria in respiratory buffer
containing 1 mM glutamate/malate were pretreated with 5 µM atractyloside. Bax at 125 nM was then
added. Swelling was monitored at 540 nm with all constituents except
Bax was added to the reference cuvette. The results are typical of 3 independent experiments utilizing 3 independent mitochondrial and Bax
preparations.

View larger version (35K):
[in a new window]
Fig. 3.
Bax induces MPT-dependent and
-independent cytochrome c release from isolated
mitochondria. Mitochondria (Mito., 0.5 mg/ml) in
respiratory buffer containing 1 mM glutamate/malate at
37 °C were either left untreated or pretreated for 5 min with 5 µM CSA. Bax at the indicated concentrations was then
added. After 15 min the mitochondria were pelleted. The resulting
supernatant (Super.) was filtered through a 0.2-µm and
then through a 0.1-µm Ultrafree Millipore membrane filter. Samples
were normalized for protein content using Coomassie Blue. 25 µg of
protein per lane was run in a SDS-polyacrylamide gel and electroblotted
onto nitrocellulose. Cytochrome c was detected using an
anti-cytochrome c monoclonal antibody and secondary rabbit
anti-mouse horseradish peroxidase. The blots were visualized using
enhanced chemiluminescence. The results are typical of 3 independent
experiments utilizing 3 independent mitochondrial and Bax
preparations.

View larger version (43K):
[in a new window]
Fig. 4.
Bax induces the release of adenylate kinase
from the mitochondrial intermembrane space. Mitochondria (0.5 mg/ml) in respiratory buffer containing 1 mM
glutamate/malate at 37 °C were either left untreated or pretreated
for 5 min with 5 µM CSA. Bax at the indicated
concentrations was then added. After 15 min the mitochondria were
pelleted. The resulting supernatant was filtered through a 0.2-µm and
then through a 0.1-µm Ultrafree Millipore membrane filter. Adenylate
kinase activity was assayed as described under "Experimental
Procedures."

View larger version (21K):
[in a new window]
Fig. 5.
Bax induces the release of matrix-entrapped
calcein that is dependent on opening of the PTP. Mitochondria (0.5 mg/ml) in respiratory buffer containing 1 mM
glutamate/malate were incubated for 15 min with calcein-AM. The
mitochondria were washed twice in fresh respiratory buffer. The
mitochondria were then either left untreated or pretreated for 5 min
with 5 µM CSA. The mitochondria were then exposed to the
indicated concentrations of Bax. An aliquot of the mitochondria was
then removed, and the fluorescence was measured at the times indicated.
The results are typical of 3 independent experiments utilizing 3 independent mitochondrial and Bax preparations.

View larger version (20K):
[in a new window]
Fig. 6.
Ceramide potentiates the induction of the MPT
by Bax. Purified recombinant Bax at 125 nM was
added to 0.5 mg/ml mitochondria in KCl-based respiratory buffer at
37 °C. C2-ceramide and dihydroceramide
(Dihydro-Cer) were added to a final concentration of 1 and
10 µM, respectively. C16-ceramide and
diacylglycerol (DAG) were added for a final concentration of
1 and 10 µM. Where utilized, mitochondria were
preincubated with CSA at a final concentration of 5 µM
before the addition of other agents. Respiration was initiated with the
addition of 1 mM glutamate/malate. The absorbance change
was monitored at 540 nm. The results are typical of 3 independent
experiments utilizing independent mitochondrial and Bax
preparations.

View larger version (18K):
[in a new window]
Fig. 7.
GD3 ganglioside potentiates induction of the
MPT by Bax. Purified recombinant Bax at 125 nM was
added to 0.5 mg/ml mitochondria in KCl-based respiratory buffer at
37 °C. GD3 ganglioside and GM3 ganglioside were added to a final
concentration of 0.5 and 10 µM, respectively. Where
utilized, mitochondria were preincubated with CSA at a final
concentration of 5 µM before the addition of other
agents. Respiration was initiated with the addition of 1 mM
glutamate/malate. The absorbance change was monitored at 540 nm. The
results are typical of 3 independent experiments utilizing independent
mitochondrial and Bax preparations.

View larger version (24K):
[in a new window]
Fig. 8.
Calcium modulates the susceptibility of
mitochondria to the MPT promoted by Bax. Low calcium-containing
mitochondria were isolated as described under "Experimental
Procedures." Purified recombinant Bax at 125 nM either
alone or in combination with 1 µM ceramide was added to
0.5 mg/ml mitochondria in KCl-based respiratory buffer at 37 °C.
Ca2+ was added in 40 µM steps. Respiration
was initiated with the addition of 1 mM glutamate/malate.
The absorbance change was monitored at 540 nm. The results are typical
of 3 independent experiments utilizing independent mitochondrial and
Bax preparations.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

m have been interpreted as
defining a mechanism of action that is independent of the PTP (28).
However, the present study suggests that the scenario whereby Bax
induces transient activation of the PTP with release of cytochrome
c despite the maintenance of mitochondrial energization and
the absence of organelle swelling can readily account for the same
previous observations.
![]()
FOOTNOTES
To whom correspondence should be addressed: Rm. 208, Jefferson
Alumni Hall, Thomas Jefferson University, Philadelphia, PA 19107. Tel.:
215-503-5066; Fax: 215-923-2218; E-mail: John.Farber@mail. tju.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Pastorino, J. G.,
Chen, S.-T.,
Tafani, M.,
Snyder, J. W.,
and Farber, J. L.
(1998)
J. Biol. Chem.
273,
7770-7775 2.
Hassouna, I.,
Wickert, H.,
Zimmerman, M.,
and Gillardon, F.
(1996)
Neurosci. Lett.
204,
85-88[CrossRef][Medline]
[Order article via Infotrieve]
3.
Yin, C.,
Knudson, C. M.,
Korsmeyer, S. J.,
and Van Dyke, T.
(1997)
Nature
385,
637-640[CrossRef][Medline]
[Order article via Infotrieve]
4.
Xiang, J.,
Chao, D. T.,
and Korsmeyer, S. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14559-14563 5.
Pastorino, J. G.,
Snyder, J. W.,
Serroni, A.,
Hoek, J. B.,
and Farber, J. L.
(1993)
J. Biol. Chem.
268,
13791-13798 6.
Petronilli, V.,
Cola, C.,
Massari, S.,
Colonna, R.,
and Bernardi, P.
(1993)
J. Biol. Chem.
268,
21939-21945 7.
Hoek, J. B.,
Nicholls, D. G.,
and Williamson, J. R.
(1980)
J. Biol. Chem.
255,
1458-1464 8.
Criss, W. E.,
Litwack, G.,
Morris, H. P.,
and Weinhouse, S.
(1970)
Cancer Res.
30,
370-375 9.
Criss, W. E.
(1970)
J. Biol. Chem.
245,
6352-6356 10.
Broekemeier, K. M.,
Dempsey, M. E.,
and Pfeiffer, D. R.
(1989)
J. Biol. Chem.
264,
7826-7830 11.
Woldegiorgis, G.,
Yousufzai, S. Y. K.,
and Shrago, E.
(1982)
J. Biol. Chem.
257,
14783-14787 12.
Nieminen, A. L.,
Saylor, A. K.,
Tesfai, S. A.,
Herman, B.,
and Lemasters, J. J.
(1995)
Biochem. J.
307,
99-106
13.
Kolesnick, R. N.,
and Krönke, M.
(1998)
Annu. Rev. Physiol.
60,
643-665[CrossRef][Medline]
[Order article via Infotrieve]
14.
De Maria, R.,
Lenti, L.,
Malisan, F.,
d'Agostino, F.,
Tomassini, B.,
Zeuner, A.,
Rippo, M. R.,
and Testi, R.
(1997)
Science
277,
1652-1655 15.
Arora, A. S.,
Jones, B. J.,
Patel, T. C.,
Bronk, S. F.,
and Gores, G. J.
(1997)
Hepatology
25,
958-963[CrossRef][Medline]
[Order article via Infotrieve]
16.
Mathias, S.,
Dressler, K. A.,
and Kolesnick, R. N.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
10009-10013 17.
Bourteele, S.,
Hausser, A.,
Doppler, H.,
Horn-Muller, J.,
Ropke, C,
Schwarzmann, G.,
Pfizenmaier, K.,
and Muller, G.
(1998)
J. Biol. Chem.
273,
31245-31251 18.
Gunter, T. E.,
Gunter, K. K.,
Sheu, S. S.,
and Gavin, C. E.
(1994)
Am. J. Physiol.
267,
C313-C339 19.
Pastorino, J. G.,
Snyder, J. W.,
Hoek, J. B.,
and Farber, J. L.
(1995)
Am. J. Physiol.
268,
C676-C685 20.
Nicolli, A.,
Petronilli, V.,
and Bernardi, P.
(1993)
Biochemistry
32,
4461-4465[CrossRef][Medline]
[Order article via Infotrieve]
21.
Igbavboa, U.,
and Pfeiffer, D. R.
(1991)
Biochim. Biophys. Acta
1059,
339-347[Medline]
[Order article via Infotrieve]
22.
Hoek, J. B.,
Walajtys-Rode, E.,
and Wang, X.
(1997)
Mol. Cell. Biochem.
174,
173-179[CrossRef][Medline]
[Order article via Infotrieve]
23.
Zou, H.,
Henzel, W. J.,
Liu, X.,
Lutschg, A.,
and Wang, X.
(1997)
Cell
90,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
24.
Li, P.,
Nijhawan, D.,
Budihardjo, I.,
Srinivasula, S. M.,
Ahmad, M.,
Alnemri, E. S.,
and Wang, X.
(1997)
Cell
91,
479-489[CrossRef][Medline]
[Order article via Infotrieve]
25.
Yang, J. C.,
and Cortopassi, G. A.
(1998)
Free Radical Biol. & Med.
24,
624-631[CrossRef][Medline]
[Order article via Infotrieve]
26.
Hüser, J.,
Rechenmacher, C. E.,
and Blatter, L. A.
(1998)
Biophys. J.
74,
2129-2137 27.
Petronilli, V.,
Miotto, G.,
Canton, M.,
Brini, M.,
Colonna, R.,
Bernardi, P.,
and Di Lisa, F.
(1999)
Biophys. J.
76,
725-734 28.
Jürgensmeier, J. M.,
Xie, Z.,
Deveraux, Q.,
Ellerby, L.,
Bredesen, D.,
and Reed, J. C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4997-5002 29.
Kluck, R. M.,
Bossy-Wetzel, E.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
Science
275,
1132-1136 30.
Yang, J.,
Liu, X.,
Bhalla, K.,
Kim, C. N.,
Ibrado, A. M.,
Cai, J.,
Peng, T. I.,
Jones, D. P.,
and Wang, X.
(1997)
Science
275,
1129-1132 31.
Finucane, D. M.,
Bossy-Wetzel, E.,
Waterhous, N. J.,
Cotter, T. G.,
and Green, D. R.
(1999)
J. Biol. Chem.
274,
2225-2233 32.
Schwandner, R.,
Wiegmann, K.,
Bernardo, K.,
Kreder, D.,
and Krönke, M.
(1998)
J. Biol. Chem.
273,
5916-5922 33.
Xu, J.,
Yeh, C. H.,
Chen, S.,
He, L.,
Sensi, S. L.,
Canzoniero, L. M. T.,
Choi, D. W.,
and Hsu, C. Y.
(1998)
J. Biol. Chem.
273,
16521-16526 34.
García-Ruiz, C.,
Colell, A.,
Marí, M.,
Morales, A.,
and Fernández-Checa, J. C.
(1997)
J. Biol. Chem.
272,
11369-11377
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. Jin, Q. Hou, T. D. Mullen, Y. H. Zeidan, J. Bielawski, J. M. Kraveka, A. Bielawska, L. M. Obeid, Y. A. Hannun, and Y.-T. Hsu Ceramide Generated by Sphingomyelin Hydrolysis and the Salvage Pathway Is Involved in Hypoxia/Reoxygenation-induced Bax Redistribution to Mitochondria in NT-2 Cells J. Biol. Chem., September 26, 2008; 283(39): 26509 - 26517. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Novgorodov, T. I. Gudz, and L. M. Obeid Long-chain Ceramide Is a Potent Inhibitor of the Mitochondrial Permeability Transition Pore J. Biol. Chem., September 5, 2008; 283(36): 24707 - 24717. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Blumenfeld How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries Oncologist, September 1, 2007; 12(9): 1044 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Marcil, K. Bourduas, A. Ascah, and Y. Burelle Exercise training induces respiratory substrate-specific decrease in Ca2+-induced permeability transition pore opening in heart mitochondria Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1549 - H1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W.-C. Li, J.-P. Liu, Y.-W. Mao, H. Xiang, J. Wang, W.-Y. Ma, Z. Dong, H. M. Pike, R. E. Brown, and J. C. Reed Calcium-activated RAF/MEK/ERK Signaling Pathway Mediates p53-dependent Apoptosis and Is Abrogated by {alpha}B-Crystallin through Inhibition of RAS Activation Mol. Biol. Cell, September 1, 2005; 16(9): 4437 - 4453. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Yehuda-Shnaidman, B. Kalderon, and J. Bar-Tana Modulation of Mitochondrial Transition Pore Components by Thyroid Hormone Endocrinology, May 1, 2005; 146(5): 2462 - 2472. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Novgorodov, Z. M. Szulc, C. Luberto, J. A. Jones, J. Bielawski, A. Bielawska, Y. A. Hannun, and L. M. Obeid Positively Charged Ceramide Is a Potent Inducer of Mitochondrial Permeabilization J. Biol. Chem., April 22, 2005; 280(16): 16096 - 16105. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Latha, W. Zhang, N. Cella, H. Y. Shi, and M. Zhang Maspin Mediates Increased Tumor Cell Apoptosis upon Induction of the Mitochondrial Permeability Transition Mol. Cell. Biol., March 1, 2005; 25(5): 1737 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. De Marchi, S. Campello, I. Szabo, F. Tombola, J.-C. Martinou, and M. Zoratti Bax Does Not Directly Participate in the Ca2+-induced Permeability Transition of Isolated Mitochondria J. Biol. Chem., September 3, 2004; 279(36): 37415 - 37422. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Choo, G. V.W. Johnson, M. MacDonald, P. J. Detloff, and M. Lesort Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release Hum. Mol. Genet., July 15, 2004; 13(14): 1407 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Batandier, X. Leverve, and E. Fontaine Opening of the Mitochondrial Permeability Transition Pore Induces Reactive Oxygen Species Production at the Level of the Respiratory Chain Complex I J. Biol. Chem., April 23, 2004; 279(17): 17197 - 17204. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Lee, I.-J. Kang, R. Bunger, and Y.-H. Kang Enhanced survival effect of pyruvate correlates MAPK and NF-{kappa}B activation in hydrogen peroxide-treated human endothelial cells J Appl Physiol, February 1, 2004; 96(2): 793 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Siskind, A. Davoody, N. Lewin, S. Marshall, and M. Colombini Enlargement and Contracture of C2-Ceramide Channels Biophys. J., September 1, 2003; 85(3): 1560 - 1575. [Abstract] [Full Text] [PDF] |